# EMERGING INFECTIOUS DISEASES RESEARCH PREVAIL I, III, V AND PREVAC MALI

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2022 · $4,819,955

## Abstract

PREVAIL I, PREVAIL III, and PREVAIL V remain incomplete, with inadequate funding remaining on current non-severable task orders to complete necessary laboratory work, data analyses, close-out activities, and publication of findings.  DCR has requested the services of Leidos Biomedical Research, Inc. to oversee the completion of the studies under a new non-severable task order.

## Key facts

- **NIH application ID:** 10714518
- **Project number:** 75N91019D00024-0-759102200018-1
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** CALVIN PROFFITT
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $4,819,955
- **Award type:** —
- **Project period:** 2022-09-16 → 2025-09-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10714518

## Citation

> US National Institutes of Health, RePORTER application 10714518, EMERGING INFECTIOUS DISEASES RESEARCH PREVAIL I, III, V AND PREVAC MALI (75N91019D00024-0-759102200018-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10714518. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*